Company: BIVIW
Filing Date: 2025-05-15
Form Type: DRS
Source: 0001520138-25-000149
Chunk: 29

Company: BIOVIE INC.
Filing Date: 2025-05-15
Form: DRS
Chunk 29
---
, levels of
activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. Such forward-looking statements concern our anticipated results and progress of our operations
in future periods, planned exploration and, if warranted, development of our properties, plans related to our business and other matters
that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of management. All statements contained herein that are not clearly historical
in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,”
“may,” “will,” “could,” “leading,” “intend,” “contemplate,” “shall”
and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are subject to a variety
of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed
or implied by the forward-looking statements. The section in this Prospectus entitled “Risk Factors” and the sections in our
periodic reports, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the “2024 Form 10-K”)
entitled “Business,” and in the 2024 Form 10-K and our Quarterly Reports on Form 10-Q for the quarterly periods ended September
30, 2024, December 31, 2024 and March 31, 2025 entitled “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations,” as well as other sections in this prospectus and the documents or reports incorporated
by reference into this prospectus, discuss some of the factors that could contribute to these differences. Forward-looking statements
in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements with respect to:

| - | our limited operating history and experience in developing and manufacturing drugs; |

| - | none of our products are approved for commercial sale; |

| - | our substantial capital needs; |

| - | product development risks; |

| - | our lack of sales and marketing personnel; |

| - | regulatory, competitive and contractual risks; |

| - | no assurance that our product candidates will obtain regulatory approval or that the results of clinical 
 studies will be favorable;                                                                               |

| - | risks related to